iSchemaView, the worldwide leader in advanced imaging for stroke, has
received approval from the Kingdom of Saudi Arabia’s Ministry of Health
(MOH), for the use of the RAPID imaging platform across the Kingdom of
Saudi Arabia. RAPID is designed to provide physicians with fast, fully
automated, and easy-to-interpret imaging that facilitates clinical
decision-making around stroke.
Hospitals and clinics that treat ischemic stroke in the Kingdom of Saudi
Arabia will now have access to RAPID’s automated CTP, MR, CTA and
ASPECTS solutions, as well as their unique mobile app that accelerates
the provision of information to support treatment decision making.
RAPID’s expansion into Saudi Arabia represents continued market growth
across the Middle East and is further confirmation that RAPID has become
the de facto standard for stoke imaging around the world.
“With RAPID’s AI framework and advanced imaging technology we aim to
help increase the number of patients that can be successfully treated
for stroke within the Kingdom of Saudi Arabia,” said Simon Canham,
iSchemaView Vice President & General Manager EMEA. “Moving forward the
country’s physicians will be able to aide performance by making
life-saving decisions faster and more easily, improving patient outcomes
and lives.”
Developed by leading stroke experts, RAPID technology has been selected
for use in several ground-breaking trials that have changed treatment
guidelines issued by both the American Heart Association and American
Stroke Association. The RAPID Artificial Intelligence framework combines
deep learning, machine learning and expert feature extraction. Together
these provide unparalleled sensitivity and specificity across stroke
modules (CT perfusion, MR diffusion and perfusion, CTA and CT ASPECT
scoring). Results are then delivered by the RAPID Intelligence Services
Platform via PACS, email, SMS/MMS, the RAPID app or corporate partner
workflow systems.
Unique in the comprehensive depth and range of its clinical validation,
RAPID is now also the imaging standard in stroke research. iSchemaView’s
imaging solution now has a research footprint across more than 300
stroke centers and more than 10 large-scale international clinical
trials. RAPID has been shown to aid in the selection of patients in
early and late-window stroke trials, including SWIFT PRIME, EXTEND IA,
DAWN, DEFUSE 3 and EXTEND, and has been granted FDA clearance for
selection of patients for both early and late window thrombectomy.
The Complete RAPID Platform includes:
-
RAPID MRI, which provides fully automated, easy to
interpret diffusion and perfusion maps that identify brain areas with
low ADC values, as well as delayed contrast arrival. RAPID MRI
perfusion automatically quantifies regions of reduced cerebral blood
flow, volume and transit time that exceed pre-specified thresholds. -
RAPID CTP, which automatically quantifies regions of reduced
cerebral blood flow, volume and transit time that exceed pre-specified
thresholds. Regions are color coded and the volumes of interest are
automatically measured. Maps (including mismatch maps) of the severity
of Tmax delays are provided using a four-color-coded scale. -
RAPID CTA, which automatically provides clear,
easy-to-interpret CTA maps that include a colored overlay to identify
brain regions with reduced blood vessel density. The severity of
reduction can be readily visualized by a simple, four-color-coded
scale. Additionally, a 3D reconstruction of the vasculature allows
physicians to rotate the image for optimal viewing of the vessels from
multiple angles. -
RAPID ASPECTS, which automatically generates a
standardized score — based on clinically validated machine learning
algorithms — that enables physicians to easily communicate about the
extent of a patient’s ischemic changes and to determine eligibility
for thrombectomy (clot removal). In addition, RAPID ASPECTS provides
clear visualization of the brain so that clinicians can better
scrutinize each region and confirm the automated score.
“Our commitment to transforming stroke care across the globe continues
as we provide more and more healthcare professionals with the most
comprehensive and intuitive suite of brain imaging solutions available
today,” said Don Listwin, CEO of iSchemaView. “With the approval of
RAPID in the Kingdom of Saudi Arabia, we are greatly expanding the
number of facilities in the Middle East that are able to address stroke
patients with the only clinically validated, next-generation imaging
technology.”
For more information about working with RAPID in the Kingdom of Saudi
Arabia, contact saikali@rapid.ai.
About iSchemaView
iSchemaView is the worldwide leader in advanced imaging for stroke.
Installed in over 1,000 hospitals, iSchemaView’s RAPID (automated CTP,
MRI, CTA and ASPECTS), with enhanced AI framework, is the most advanced
stroke imaging platform. In clinical trials, RAPID has been shown to aid
in the selection of patients in early and late-window stroke trials,
including SWIFT PRIME, EXTEND IA, DAWN, DEFUSE 3 and EXTEND. In addition
to achieving the best clinical outcomes and largest treatment effects
ever obtained, these landmark studies led to new American Heart
Association and American Stroke Association guidelines and have
dramatically altered the management of acute stroke around the
world. For more information, visit www.RAPID.ai
View source version on businesswire.com: https://www.businesswire.com/news/home/20190416005220/en/